Stockscreener 앱 받기
0.6027
4.79%
-0.0303
시장 영업 전:
.69
0.0873
+14.48%
전일 마감가:
$0.633
열려 있는:
$0.6313
하루 거래량:
111.87K
Relative Volume:
1.88
시가총액:
$2.46M
수익:
-
순이익/손실:
$-11.91M
주가수익비율:
-0.068
EPS:
-8.8661
순현금흐름:
$-10.83M
1주 성능:
-5.38%
1개월 성능:
-50.19%
6개월 성능:
-79.84%
1년 성능:
-96.06%
1일 변동 폭
$0.59
$0.64
1주일 범위
$0.5501
$0.67
52주 변동 폭
$0.473
$22.36
Silexion Therapeutics Corp Stock (SLXN) Company Profile
명칭
Silexion Therapeutics Corp
전화
972-8-6286005
주소
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.6027 | 2.46M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Silexion Therapeutics Corp 주식(SLXN)의 최신 뉴스
Silexion Therapeutics Shareholders Approve Capital Increase, Reverse Split - TipRanks
[8-K] Silexion Therapeutics Corp Reports Material Event - Stock Titan
SLXN (Silexion Therapeutics) posts wider than expected Q4 2025 loss, pushing shares 3.01 percent lower in today’s trading.Investor Call - Newser
SLXN (Silexion Therapeutics) posts wider than expected Q4 2025 loss, shares dip 0.94% in today’s trading. - Newser
Silexion Therapeutics Submits Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Pancreatic Cancer - Minichart
Silexion advances SIL204 to EU Phase 2/3 pancreatic trial - TipRanks
Silexion (NASDAQ: SLXN) advances SIL204 with German CTA step - Stock Titan
Pancreatic cancer drug SIL204 moves toward EU mid-stage trial - Stock Titan
Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN
What FIFO method Silexion Therapeutics (SLXN)? (Ticks Higher) 2026-04-27Hedge Fund Inspired Picks - Newser
Silexion stock jumps after toxicology studies show no systemic toxicity - MSN
Is Silexion Therapeutics (SLXN) stock undervalued compared to fundamentals | Q4 2025: Profit DisappointsTrending Buy Opportunities - Xã Thanh Hà
SLXN (Silexion Therapeutics Corp Ordinary Shares) rises seven percent even as Q4 2025 EPS falls short of analyst expectations.Trader Community Insights - Cổng thông tin điện tử tỉnh Tây Ninh
SLXN (Silexion Therapeutics Corp Ordinary Shares) misses Q4 2025 EPS estimates, shares drop 1.92% on cautious investor sentiment.Shared Momentum Picks - UBND thành phố Hải Phòng
SLXNW SEC FilingsSilexion Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
SLXN Stock Price, Quote & Chart | SILEXION THERAPEUTICS CORP (NASDAQ:SLXN) - ChartMill
Silexion (SLXN) plans big share boost, richer equity pool and reverse split - Stock Titan
Aug Chart Watch: Whats the profit margin of Silexion Therapeutics Corp2026 Geopolitical Influence & Safe Entry Point Alerts - baoquankhu1.vn
Institution Moves: Is Silexion Therapeutics Corp a strong growth stock2026 Selloffs & Weekly Market Pulse Updates - baoquankhu1.vn
Are short sellers targeting Silexion (SLXNW) Stock | Price at $0.01, Up 7.14%Fundamentals - Newser
CEO Moves: What is the PEG ratio of Silexion Therapeutics Corp Equity Warrant2026 Market Trends & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Fed Watch: Does GLBS stock have upside surprise potential2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Can Silexion Therapeutics Corp stock beat analyst upgradesMarket Growth Report & AI Driven Stock Price Forecasts - Bollywood Helpline
ETF Watch: Can Silexion Therapeutics Corp Equity Warrant expand its profit margins - baoquankhu1.vn
Is Silexion Therapeutics (SLXN) Stock Showing Strength | Price at $1.17, Down 2.51%Crowd Trend Signals - Newser
SLXNW Stock Analysis: Silexion Therapeutics Corp Warrant Falls 31% to $0.01 Level - UBND thành phố Hải Phòng
EBIT per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView — Track All Markets
Hedge Fund Bets: Will Silexion Therapeutics Corp Equity Warrant benefit from government policy2026 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Market Recap: Whats the profit margin of Silexion Therapeutics Corp2026 Historical Comparison & Technical Entry and Exit Alerts - baoquankhu1.vn
Shorts Report: Whats the beta of Silexion Therapeutics Corp Equity Warrant stock2026 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Top Silexion Executive Quietly Unloads a Chunk of Company Stock - TipRanks
Silexion Therapeutics (SLXN) CSO logs sale-to-cover share transaction - Stock Titan
Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors - MSN
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Trial of SIL204 in Locally Advanced Pancreatic Cancer - geneonline.com
Investor Mood: Can Silexion Therapeutics Corp be recession proofWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Silexion Therapeutics Announces Immediate Board Membership Change - tipranks.com
Ilan Levin removed from Silexion Therapeutics board - TradingView
Board at Silexion Therapeutics (NASDAQ: SLXN) removes Ilan Levin - Stock Titan
Is Silexion Therapeutics Corp a strong growth stockMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204 - TipRanks
Silexion Shareholders Reject Capital Increase and Plan Amendments - The Globe and Mail
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Clinical Trial of SIL204 in Advanced Pancreatic Cancer - minichart.com.sg
Silexion gets Israeli approval for pancreatic cancer trial - Investing.com
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire
Silexion Therapeutics Corp (SLXN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):